Investor Presentaiton
Financial Results for Q4 FY2022
Marketing Status of MYFEMBREEⓇ
Approx. 19,700 total prescriptions (TRX) in Q4
FY2022 (29% growth vs. Q3 FY2022)
+29%
19,783
15,380
10,406
7,664
4,924
2,572
469
Q2
FY2021
Q3
Q4
Q1
Q2
Q3
Q4
FY2021 FY2021 FY2022 FY2022 FY2022 FY2022
Number of prescriptions per quarter with MYFEMBREE®*
The market targeted by MYFEMBREEⓇ is approx. 63 billion
yen/year (gross conversion), and recently expanded by approx.
20% annually**
Also focus on switching from oral contraceptives, NSAIDs,
and surgery to MYFEMBREEⓇ
Established broad health plan coverage (Percentage of total
commercial lives as primary coverage obtained as of March
2023; for UF was >90% and endo. was >80%)
■Gathering new evidence for further potential utility
(To leverage data of long-term administration for endo. and
verify contraceptive efficacy)
■ Continue to improve Gross to Net
*Source Symphony Health, an ICON plc Company, IDVⓇ
**Source IQVIA NSP sales as of end of Feb. 2023 and TRX as of
end of Mar. 2023. Sales for MYFEMBREE®, ORIAHNN, ORILISSA,
Lupron Depot 3.75MG/11.25MG, and Lupaneta Pack for the 12
months ended Feb. 2023 were $481M (130yen/$), which reflects a
19% growth vs 12 months ended Feb. 2022View entire presentation